{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:07:22Z","timestamp":1789448842759,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:00:00Z","timestamp":1474588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11883-016-0611-4","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T09:24:07Z","timestamp":1474622647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase"],"prefix":"10.1007","volume":"18","author":[{"given":"Ozlem","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"611_CR1","first-page":"S36","volume":"15","author":"DM Kolansky","year":"2009","unstructured":"Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15:S36\u201341.","journal-title":"Am J Manag Care"},{"key":"611_CR2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","volume":"46","author":"SD Wiviott","year":"2005","unstructured":"Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"611_CR3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711\u20138.","journal-title":"JAMA"},{"key":"611_CR4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"JA Lemos de","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307\u201316.","journal-title":"JAMA"},{"key":"611_CR5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/clc.22343","volume":"37","author":"SS Virani","year":"2014","unstructured":"Virani SS, Woodard LD, Akeroyd JM, et al. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology\/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014;37:653\u20139.","journal-title":"Clin Cardiol"},{"key":"611_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","volume":"18","author":"CR Harper","year":"2007","unstructured":"Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18:401\u20138.","journal-title":"Curr Opin Lipidol"},{"key":"611_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","volume":"105","author":"M Alberton","year":"2012","unstructured":"Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM. 2012;105:145\u201357.","journal-title":"QJM"},{"key":"611_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","volume":"172","author":"AL Culver","year":"2012","unstructured":"Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women\u2019s Health Initiative. Arch Intern Med. 2012;172:144\u201352.","journal-title":"Arch Intern Med"},{"key":"611_CR9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2015.05.003","volume":"9","author":"ND Wong","year":"2015","unstructured":"Wong ND, Chuang J, Zhao Y, Rosenblit PD. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. J Clin Lipidol. 2015;9:525\u201332.","journal-title":"J Clin Lipidol"},{"key":"611_CR10","doi-asserted-by":"crossref","first-page":"e47681","DOI":"10.1371\/journal.pone.0047681","volume":"8","author":"F Gao","year":"2013","unstructured":"Gao F, Zhou YJ, Hu da Y, et al. Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. PLoS One. 2013;8:e47681.","journal-title":"PLoS One"},{"key":"611_CR11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacl.2015.01.002","volume":"9","author":"HN Lemus","year":"2015","unstructured":"Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015;9:384\u20139. Review of the function of ACL and its clinical implications.","journal-title":"J Clin Lipidol"},{"key":"611_CR12","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","volume":"51","author":"Q Wang","year":"2010","unstructured":"Wang Q, Li S, Jiang L, et al. Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice. J Lipid Res. 2010;51:2516\u201326.","journal-title":"J Lipid Res"},{"key":"611_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0304-4165(68)90071-8","volume":"158","author":"Y Daikuhara","year":"1968","unstructured":"Daikuhara Y, Tsunemi T, Takeda Y. The role of ATP citrate lyase in the transfer of acetyl groups in rat liver. Biochim Biophys Acta. 1968;158:51\u201361.","journal-title":"Biochim Biophys Acta"},{"key":"611_CR14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","volume":"63","author":"F Ameer","year":"2014","unstructured":"Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism. 2014;63:895\u2013902.","journal-title":"Metabolism"},{"key":"611_CR15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1568013033483357","volume":"3","author":"PHE Groot","year":"2003","unstructured":"Groot PHE, Pearce NJ, Gribble AD. ATP-citrate lyase: a potential target for hypolipidemic intervention. Curr Med Chem Immunol Endocr Metab Agents. 2003;3:211\u20137. Review of the role of ACL in lipogenesis.","journal-title":"Curr Med Chem Immunol Endocr Metab Agents"},{"key":"611_CR16","unstructured":"Esperion Therapeutics. Understanding key pathways. Available at: http:\/\/www.esperion.com\/ourpathways-approach\/understanding-key-pathways\/ . Accessed 20 January 2016."},{"key":"611_CR17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","volume":"272","author":"TA Berkhout","year":"1990","unstructured":"Berkhout TA, Havekes LM, Pearce NJ, Groot PH. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J. 1990;272:181\u20136.","journal-title":"Biochem J"},{"key":"611_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02533284","volume":"12","author":"JG Hamilton","year":"1977","unstructured":"Hamilton JG, Sullivan AC, Kritchevsky D. Hypolipidemic activity of (-)-hydroxycitrate. Lipids. 1977;12:1\u20139.","journal-title":"Lipids"},{"issue":"Pt 1","key":"611_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj3340113","volume":"334","author":"NJ Pearce","year":"1998","unstructured":"Pearce NJ, Yates JW, Berkhout TA, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998;334(Pt 1):113\u20139.","journal-title":"Biochem J"},{"key":"611_CR20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134\u201351.","journal-title":"J Lipid Res"},{"key":"611_CR21","unstructured":"Hanselman JC, Bradshaw CD, Brant AF, et al. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice (abstract 657). Presented at ATVB Scientific Sessions 2011, Chicago, IL, 28\u201330 April 2011."},{"key":"611_CR22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","volume":"54","author":"S Filippov","year":"2013","unstructured":"Filippov S, Pinkosky SL, Lister RJ, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013;54:2095\u2013108.","journal-title":"J Lipid Res"},{"key":"611_CR23","unstructured":"Esperion Therapeutics I. Form 10-K - Annual report United States Securities and Exchange Commission. 10 March 2015. Available at: http:\/\/www.sec.gov\/Archives\/edgar\/data\/1434868\/000104746915001908\/0001047469-15-001908-index.htm . Accessed 20 January 2016."},{"key":"611_CR24","unstructured":"ClinicalTrials.gov. A multiple ascending dose study of ETC-1002 in subjects with mild dyslipidemia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01105598 . Accessed 20 January 2016."},{"key":"611_CR25","unstructured":"ClinicalTrials.gov. A multiple ascending dose study of ETC-1002 in healthy subjects. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01485146 . Accessed 20 January 2016."},{"key":"611_CR26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154\u201362. First phase 2 trial which studied LDL-C\u2013lowering efficacy and safety of ETC-1002 versus placebo in patients with hypercholesterolemia.","journal-title":"J Am Coll Cardiol"},{"key":"611_CR27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"611_CR28","unstructured":"ClinicalTrials.gov. Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02178098 . Accessed 20 January 2016."},{"key":"611_CR29","unstructured":"ClinicalTrials.gov. A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01779453 . Accessed 20 January 2016."},{"key":"611_CR30","doi-asserted-by":"crossref","first-page":"A17499","DOI":"10.1161\/circ.132.suppl_3.17499","volume":"132","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM, Macdougall DE, Margulies JR, et al. ETC-1002 incrementally lowers low density lipoprotein-cholesterol in patients with hypercholesterolemia receiving stable statin therapy [abstract 17499]. Circulation. 2015;132:A17499.","journal-title":"Circulation"},{"key":"611_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295\u2013304.","journal-title":"J Clin Lipidol"},{"key":"611_CR32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Macdougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10:556\u201367. Study showed that LDL-C lowering was most pronounced when ETC-1002 was combined with ezetimibe in patients with a history of statin intolerance.","journal-title":"J Clin Lipidol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-016-0611-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T02:18:24Z","timestamp":1657333104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-016-0611-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1007\/s11883-016-0611-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,23]]},"article-number":"61"}}